ERBB2 and neoplasm: Based on the above analysis, we then constructed a HER2‐targeted STING agonist delivery ISAC with excellent antitumor effects in multiple tumor cell models, and its antitumor effects are superior to those of other marketed HER2‐ADCs (e.g., DS‐8201 and T‐DM1).